DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,209,246 | -4.3% | 107,089 | +36.8% | 0.01% | 0.0% |
| Q2 2023 | $2,309,246 | +28.1% | 78,253 | 0.0% | 0.01% | +33.3% |
| Q1 2023 | $1,802,949 | -17.2% | 78,253 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $2,176,216 | -9.4% | 78,253 | 0.0% | 0.01% | -20.0% |
| Q3 2022 | $2,402,000 | -11.2% | 78,253 | -14.8% | 0.01% | 0.0% |
| Q2 2022 | $2,705,000 | +9.3% | 91,898 | +19.5% | 0.01% | +25.0% |
| Q1 2022 | $2,475,000 | -6.9% | 76,931 | +29.0% | 0.01% | 0.0% |
| Q4 2021 | $2,659,000 | -3.0% | 59,618 | +9.8% | 0.01% | 0.0% |
| Q3 2021 | $2,740,000 | -31.3% | 54,308 | +6.8% | 0.01% | -38.5% |
| Q2 2021 | $3,989,000 | +41.8% | 50,860 | +3.2% | 0.01% | +30.0% |
| Q1 2021 | $2,813,000 | -40.0% | 49,271 | -12.1% | 0.01% | -41.2% |
| Q4 2020 | $4,692,000 | +81.5% | 56,023 | -22.4% | 0.02% | +70.0% |
| Q3 2020 | $2,585,000 | +27.5% | 72,159 | -14.0% | 0.01% | +25.0% |
| Q2 2020 | $2,028,000 | – | 83,876 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |